Combining GLP-1 medications with 8 healthy lifestyle habits reduced the risk of major adverse cardiovascular events, or MACE, ...

By Hugo Francisco de Souza A sweeping Lancet review reveals how modern incretin-based drugs are reshaping treatment for ...

The search for long COVID treatments continues, as a randomized clinical trial found that a two-week course of metformin or ursodeoxycholic acid (UDCA) did not meaningfully improve recovery from ...

Researchers are developing a two-part therapy for type 1 diabetes: lab-made insulin-producing cells paired with ...

The provincial and federal governments signed a four-year agreement last year to implement a national PharmaCare initiative ...

The study emphasizes the importance of vigilance with diet and exercise, among other things, to reduce CV risk in type 2 ...

The national PharmaCare program will start in British Columbia on Sunday, giving residents free access to a variety of ...

A recent study found that combing GLP-1 drugs with healthy lifestyle habits may help reduce cardiovascular risk in people with diabetes.

Drugmaker Lilly said its experimental pill, orforglipron, produced better blood sugar and weight loss for diabetes patients results in a new head-to-head clinical trial.

A new daily pill could offer a major breakthrough for people living with type 2 diabetes and struggling with weight management ...